<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yunusa I</submitter><funding>NIA NIH HHS</funding><funding>AHRQ HHS</funding><funding>NIAMS NIH HHS</funding><pagination>e220194</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8874341</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>5(2)</volume><pubmed_abstract>&lt;h4>Importance&lt;/h4>Some selective serotonin reuptake inhibitors (SSRIs) inhibit the enzymes responsible for the metabolism of oxycodone, a potent prescription opioid. The clinical consequences of this interaction on the risk of opioid overdose have not been elucidated.&lt;h4>Objective&lt;/h4>To compare opioid overdose rates in patients initiating oxycodone while taking SSRIs that are potent inhibitors of the cytochrome-P450 2D6 enzyme (CYP2D6) vs SSRIs that are not.&lt;h4>Design, setting, and participants&lt;/h4>This cohort study included adults who initiated oxycodone while receiving SSRI therapy between 2000 and 2020 whose data were included in 3 US health insurance databases.&lt;h4>Exposures&lt;/h4>Use of SSRIs that strongly inhibit CYP2D6 enzyme (fluoxetine or paroxetine) vs use of other SSRIs at the ti</pubmed_abstract><journal>JAMA network open</journal><pubmed_title>Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors.</pubmed_title><pmcid>PMC8874341</pmcid><funding_grant_id>K23 AR076453</funding_grant_id><funding_grant_id>K01 AG068365</funding_grant_id><funding_grant_id>R01 HS027623</funding_grant_id><pubmed_authors>Gagne JJ</pubmed_authors><pubmed_authors>Yunusa I</pubmed_authors><pubmed_authors>Bykov K</pubmed_authors><pubmed_authors>Yoshida K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors.</name><description>&lt;h4>Importance&lt;/h4>Some selective serotonin reuptake inhibitors (SSRIs) inhibit the enzymes responsible for the metabolism of oxycodone, a potent prescription opioid. The clinical consequences of this interaction on the risk of opioid overdose have not been elucidated.&lt;h4>Objective&lt;/h4>To compare opioid overdose rates in patients initiating oxycodone while taking SSRIs that are potent inhibitors of the cytochrome-P450 2D6 enzyme (CYP2D6) vs SSRIs that are not.&lt;h4>Design, setting, and participants&lt;/h4>This cohort study included adults who initiated oxycodone while receiving SSRI therapy between 2000 and 2020 whose data were included in 3 US health insurance databases.&lt;h4>Exposures&lt;/h4>Use of SSRIs that strongly inhibit CYP2D6 enzyme (fluoxetine or paroxetine) vs use of other SSRIs at the ti</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Feb</publication><modification>2025-04-04T12:44:09.936Z</modification><creation>2025-04-04T12:44:09.936Z</creation></dates><accession>S-EPMC8874341</accession><cross_references><pubmed>35201310</pubmed><doi>10.1001/jamanetworkopen.2022.0194</doi></cross_references></HashMap>